[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634671":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":19,"locations":19,"responsibleParty":20,"collaborators":19,"id":22,"slug":23,"hasResults":24,"nctId":25,"briefTitle":26,"officialTitle":27,"acronym":19,"eligibilityCriteria":28,"healthyVolunteers":24,"sex":29,"minAge":30,"maxAge":19,"enrollmentInfo":31,"targetDuration":19,"studyType":34,"phases":35,"briefSummary":38,"conditions":39,"keywords":41,"overallStatus":46,"whyStopped":19,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":19},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"treatment","EXPERIMENTAL","MRG003 \\[Becotatug vedotin, an epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC)\\]: 2.0 mg\u002Fkg IV infusion, Day 1, every 3 weeks QL1706 \\[Iparomlimab and tuvonralimab, a bifunctional anti-programmed death-1\u002Fcytotoxic T-lymphocyte antigen-4 antibody\\]: 5 mg\u002Fkg IV infusion, Day 1, every 3 weeks Each treatment cycle is 21 days. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, initiation of new anti-tumor therapy, or death.",[13],"Drug: Treatment",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","Treatment",[9],null,{"type":21,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100634671","phase-1-ascerv-study-mrg003-combined-with-ql1706-in-recurrent-or-metastatic-cervical-cancer-100634671",false,"NCT07542717","ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer","A Single-Arm, Multicenter, Phase II Study of MRG003 Combined With QL1706 for Second-Line or Later Treatment of Recurrent or Metastatic Cervical Cancer (ASCERV Study)","Inclusion Criteria:\n\nAge ≥18 years Histologically confirmed recurrent or metastatic cervical cancer (squamous, adenocarcinoma, or adenosquamous) Progression after ≥1 line of platinum-based therapy At least one measurable lesion per RECIST v1.1 ECOG performance status 0-1 Life expectancy ≥12 weeks Adequate organ function Recovery from prior treatment toxicities (≤ Grade 1) Agreement to use effective contraception Signed informed consent\n\nExclusion Criteria:\n\nActive malignancy within 5 years (except certain cured cancers) Active CNS metastases Significant cardiovascular disease Uncontrolled comorbidities Active hepatitis B\u002FC or uncontrolled HIV infection Interstitial lung disease or pneumonitis Prior EGFR-targeted therapy Prior T-cell co-stimulatory pathway agents Recent live vaccination Use of strong CYP3A4 inhibitors\u002Finducers Pregnancy or breastfeeding Any condition deemed unsuitable by investigator","FEMALE","18 Years",{"count":32,"type":33},41,"ESTIMATED","INTERVENTIONAL",[36,37],"PHASE1","PHASE2","This is a single-arm, multicenter, phase II study designed to evaluate the efficacy and safety of MRG003, an anti-EGFR antibody-drug conjugate, in combination with QL1706, a PD-1\u002FCTLA-4 bispecific antibody, in patients with recurrent or metastatic cervical cancer who have failed prior platinum-based therapy.",[40],"Recurrent or Metastatic Cervical Cancer",[42,43,44,45],"Metastatic Cervical Cancer","MRG003","QL1706","Second-Line or Later Treatment","NOT_YET_RECRUITING","2026-04-17",{"date":49,"type":50},"2026-04-21","ACTUAL",{"date":52,"type":33},"2026-04-10",{"date":54,"type":33},"2030-03-31",{"name":5,"class":6}]